Business / Finance

RSS

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Bruker second quarter revenue increases 33% y-o-y to $401.2 million

Bruker Corporation today reported financial results for the three and six months ended June 30, 2011.

3 Aug 2011

Medical Action first quarter net sales increase 59% to $106,473,000

Medical Action Industries Inc., a leading supplier of medical and surgical disposable products, today reported results for the fiscal 2012 first quarter ended June 30, 2011.

3 Aug 2011

NxStage second quarter revenue increases 22% to $53.8 million

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported record financial results for the second quarter of 2011 ended June 30, 2011, with total revenue well above the top end of its guidance range.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

Aerogen receives Ruban d'Honneur award for global growth strategy

Irish company Aerogen, a medical device and drug delivery company has been awarded the internationally prestigious Ruban d'Honneur award in the European Business Awards.

3 Aug 2011

BioClinica second quarter service revenues increase 8.7% to $16.9 million

BioClinica Inc., a global provider of clinical trial management solutions, today announced its financial results for the second quarter and six months ended June 30, 2011.

From Clario 3 Aug 2011

SXC enters definitive agreement to acquire PTRx

SXC Health Solutions Corp. announced today that it has entered into a definitive agreement to acquire PTRx, Inc., a full-service PBM, and SaveDirectRx, Inc., its exclusive mail-order pharmacy provider, both based in San Antonio.

3 Aug 2011

Illumina board authorizes new $100 million share repurchase program

Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.

From Illumina, Inc. 3 Aug 2011

Artimplant reports net revenue of SEK 9.7 million for January – June, 2011

Artimplant: First six months: Net revenue amounted to SEK 9.7 million.

3 Aug 2011

SFS completes $5.7M financing for new outpatient surgery center

Siemens Financial Services, Inc., the U.S. unit of Siemens' Financial Services division, recently completed a $5.7 million financing to support the development of a new outpatient surgery center, doing business as the Surgery Center of Anchorage located in Anchorage, Alaska.

3 Aug 2011

MSMB offers $18 per share for Amag acquisition

MSMB Capital Management today announced that it has made a proposal to the Board of Directors of Amag Pharmaceuticals Inc. to acquire all of the outstanding shares of common stock of Amag for $18 per share in cash or an aggregate of $378 million.

3 Aug 2011

Akorn enters agreement to acquire minority ownership in Aciex

Akorn, Inc., a niche specialty pharmaceutical company, today announced that it has entered into an agreement to acquire a minority ownership in Westborough, MA, based Aciex Therapeutics Inc., an ophthalmic drug development company with a focus on developing novel therapeutics to treat ocular diseases.

3 Aug 2011

BioSante closes underwritten public offering of common stock

BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.

3 Aug 2011

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer Inc. today reported financial results for second-quarter 2011. As a result of Pfizer's decision to sell the Capsugel business, all revenues and expenses related to Capsugel in all periods presented are reflected in a single line, Discontinued operations - net of tax.

3 Aug 2011

AtriCure second quarter revenue increases 18.2% to $16.8 million

AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and systems for the exclusion of the left atrial appendage, today announced financial results for the second quarter of 2011. Revenue was $16.8 million, reflecting 18.2 percent growth over the second quarter of 2010.

2 Aug 2011